Aimmune teams with Regeneron, Sanofi on peanut allergy drug

(Reuters) - Aimmune Therapeutics Inc said on Monday it would collaborate with Regeneron Pharmaceuticals Inc and Sanofi to develop its experimental peanut allergy drug. The company said it would test the drug, AR101, in combination with Regeneron and Sanofi's dupilumab in a mid-stage trial that is expected to start in 2018 and will be sponsored by Regeneron. AR101, an oral immunotherapy, is already being tested as a mono-therapy for peanut allergy in a late-stage trial.

from RSSMix.com Mix ID 8259690 http://ift.tt/2ymk1tO